ongitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients

• Conditions: non-small cell lung cancer; 10038666

• Registration Number: NL-OMON37300
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

• Histologically or cytologically proven irresectable stage III or IV non-small cell lung cancer
• Age above 18 years
• Performance score: WHO 0, 1 or 2 at the time of study entry
• Written informed consent
• Specific inclusion criteria for tissue biopsies:
- Only target lesion with limited biopsy-procedure related complication risk will be sampled; For instance easily accessible peripheral lymph nodes, subcutaneous, pleural, liver metastastasis.
- Other lesions will only be included if there is a clinical necessity for tissue analysis (e.g. molecular profiling, resection metastasis in case of oligometastastic disease).
- Only non-irradiated lesions will be sampled

Exclusion Criteria

• Severe anemia (Hb < 6.0 mmol/L)
• Any bleeding disorder or anti-coagulation therapy, that cannot be discontinued or corrected, that significantly increases the risk of a bleeding due to the biopsy.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The longitudinal effects of treatment for irresectable stage III or IV<br /><br>non-small cell lung cancer on tumor material obtained by surgical<br /><br>removal/biopsies and on peripheral blood components.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>